Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session

Johnson & Johnson

The companies will be collaborating on immuno-oncology treatments.

Fate Therapeutics Snags $3 Billion-Plus Deal With Johnson & Johnson

The cellular therapy developer announced an equity investment from and a partnership with Janssen, a subsidiary of Johnson & Johnson.

Here's Why Fate Therapeutics Rose as Much as 18.7% Today

Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.

Fate Therapeutics Surges on Immunotherapy Deal With J&J

ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ꟷ

Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

SAN DIEGO, April  02, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in the Company’s first-in-human Phase 1 clinical trial evaluating FT596, the first cell therapy product candidate engineered with three active anti-tumor modalities, in patients with B-cell malignancies and chronic lymphocytic leukemia. FT596 is an off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a proprietary CD19-targeting CAR, a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, and a unique interleukin-15 receptor fusion (IL-15RF). The hnCD16 Fc receptor enables coincident targeting of additional tumor-associated antigens expressed on cancer cells to overcome antigen escape, and IL-15RF is a potent cytokine complex that promotes survival, proliferation and trans-activation of NK cells and CD8 T cells without the need for systemic cytokine support.

Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

Fate Therapeutics: Potential Catalysts Ahead

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript

Iovance Biotherapeutics

These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.

2 Top Biotech  Stocks to Buy Right Now

FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies

Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

Axsome Therapeutics

Pfizer

Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.

3 Top Drug Stocks to Own In 2020

Forecasting 2020 For Fate Therapeutics

argenx

bluebird bio

Blueprint Medicines

Epizyme

Magenta Therapeutics Inc

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Wedbush’s Top Picks After ASH Annual Meeting

Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

Fate (FATE) Announces Encouraging Data on Immunotherapies

Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE) FT500 and FT516 therapies were well received by both clinicians and investors, according to Wells Fargo.

Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

The ambitious cellular medicine developer finally has clinical results for investors to ponder. It's still early, but the updates are promising.

Fate Therapeutics Soars as Much as 45.8% After Giving Investors What They Wanted

These companies are carving their own paths in cellular medicines. One just posted promising clinical results, while the other aims to do so this month.

2 Top Biotech Stocks to Buy in December

Fate Therapeutics Inc. (NASDAQ: FATE) shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line at the American Society of Hematology (ASH) annual meeting.

Why Fate Therapeutics Is One of ASH’s Biggest Winners

Shares of Fate Therapeutics  gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in a very small Phase 1 trial as treatments for acute myeloid leukemia and as a combination therapy for advanced B-cell lymphoma.

Fate Therapeutics' stock rises on early-stage cancer drug data

FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma

Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle

Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

There's a lot of action in the company's pipeline, which investors are taking time to digest.

Here's Why Fate Therapeutics Dropped as Much as 19.9% Today

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2019 Results - Earnings Call Transcript

SAN DIEGO, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 9,890,000 shares of its common stock, which included 1,290,000 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.50 per share.  Aggregate gross proceeds from this offering, including exercise of the option, were approximately $173.1 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical research and development, and for general corporate purposes.

News for Fate Therapeutics Stock (FATE)